Clinical Trials in San Antonio

Showing 5241-5260 of 11,125 trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic \[Tc\] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.

COVID-19SARS-CoV2

SAb Biotherapeutics, Inc.28 participantsStarted Jul 2020

Wichita, Kansas, United States • Syracuse, New York, United States • San Antonio, Texas, United States

COMPLETEDPhase 2< 1 mile

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01235936

The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.

AnemiaKidney Disease

Akebia Therapeutics10 participantsStarted Oct 2010

Augusta, Georgia, United States • San Antonio, Texas, United States

TERMINATEDPhase 3< 1 mile

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

NCT03400956

The primary objective of this study was to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids

Uterine Fibroids

Bayer103 participantsStarted Jan 2018

Canyon Country, California, United States • Encinitas, California, United States • Huntington Park, California, United States +84 more locations

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

Find Trials by Condition in San Antonio

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Safety Study of the VEGA UV-A System to Treat Ectasia

Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia

SHIELD II Clinical Investigation

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

MOMENTUM 3 IDE Clinical Study Protocol

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation

CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Esteem New Subject Enrollment Post Approval Study

Cooled RFA vs Conventional RFA to Manage Chronic Facetogenic Low Back Pain

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)